文献速递认知障碍与痴呆

KLOTHO杂合性减轻临床前阿尔茨海默病中APOE4相关淀粉样蛋白负担

KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.
PubMed 文献 · Neurology · 2019-03-13

结果显示APOE4携带者淀粉样蛋白负担更高,但该效应仅在KL-VS非携带者中显著,而在KL-VS杂合子中APOE4阳性与阴性者无差异。

要点

  • APOE4携带者脑脊液和PiB-PET的Aβ负担均高于非携带者。
  • KL-VS非携带者中APOE4对Aβ的效应显著,杂合子中无显著差异。
  • KL-VS杂合性可能缓冲APOE4相关Aβ聚集。

核心结论

  • 在晚中年高危人群中,KL-VS杂合性与APOE4相关Aβ聚集减轻相关,提示其可能保护APOE4致病通路。

主要发现

  • APOE4携带者Aβ负担高于APOE4阴性者,脑脊液效应(t=-5.12,p<0.001)强于PiB-PET(t=3.93,p<0.001)。
  • 在KL-VS非携带者中,APOE4对Aβ负荷的效应重现(脑脊液:t=-5.09,p<0.001;PiB-PET:t=3.77,p<0.001)。
  • 在KL-VS杂合子中,APOE4阳性者与阴性者的Aβ负担无显著差异(脑脊液:t=-1.03,p=0.308;PiB-PET:t=0.92,p=0.363)。
  • KL-VS杂合子与非携带者按年龄和性别匹配后,APOE4效应的差异仍存在。

临床怎么用

  • 在临床前AD风险评估中,可考虑结合KL-VS与APOE4基因型解读Aβ负担差异。

局限性

  • 研究队列为晚中年高危成人,未包含KL-VS纯合个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether the KLOTHO gene variant KL-VS attenuates APOE4-associated β-amyloid (Aβ) accumulation in a late-middle-aged cohort enriched with Alzheimer disease (AD) risk factors. METHODS: Three hundred nine late-middle-aged adults from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center were genotyped to determine KL-VS and APOE4 status and underwent CSF sampling (n = 238) and/or 11C-Pittsburgh compound B (PiB)-PET imaging (n = 183). Covariate-adjusted regression analyses were used to investigate whether APOE4 exerted expected effects on Aβ burden. Follow-up regression analyses stratified by KL-VS genotype (i.e., noncarrier vs heterozygous; there were no homozygous individuals) evaluated whether the influence of APOE4 on Aβ was different among KL-VS heterozygotes compared to noncarriers. RESULTS: APOE4 carriers exhibited greater Aβ burden than APOE4-negative participants. This effect was stronger in CSF (t = -5.12, p < 0.001) compared with PiB-PET (t = 3.93, p < 0.001). In the stratified analyses, this APOE4 effect on Aβ load was recapitulated among KL-VS noncarriers (CSF: t = -5.09, p < 0.001; PiB-PET: t = 3.77, p < 0 .001). In contrast, among KL-VS heterozygotes, APOE4-positive individuals did not exhibit higher Aβ burden than APOE4-negative individuals (CSF: t = -1.03, p = 0.308; PiB-PET: t = 0.92, p = 0.363). These differential APOE4 effects remained after KL-VS heterozygotes and noncarriers were matched on age and sex. CONCLUSION: In a cohort of at-risk late-middle-aged adults, KL-VS heterozygosity was associated with an abatement of APOE4-associated Aβ aggregation, suggesting KL-VS heterozygosity confers protections against APOE4-linked pathways to disease onset in AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Erickson CM, Schultz SA, Oh JM, et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology. 2019. PMID: 30867273. doi:10.1212/WNL.0000000000007323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。